Listed by the USPTO as NEAGU, IRINA
Tech Center 1700 • Art Units: 1627 1629 1764
This examiner grants 47% of resolved cases
NEAGU, IRINA has resolved 719 cases in Tech Center 1700 and Art Unit 1627. The allowance rate is 46.7%, while the median time to allowance is 1010 days. The record indicates a challenging allowance environment despite a prosecution timeline that is not as extended as some other profiles. Applicants should invest in claim differentiation, evidence, and a clear response strategy from the first substantive exchange.
The interview lift is 57.2%, a strong positive association that makes interview preparation particularly relevant. Keto Innovations LLC, Dana-Farber Cancer Institute Inc., and BASF SE are the leading listed companies. Clark+Elbing LLP, Ferguson Braswell Fraser Kubasta PC, and MCKEE, VOORHEES & SEASE, P.L.C. are the principal listed firms. Practitioners should still treat the interview signal as contextual rather than determinative.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18576068 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 AND USES THEREOF | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 17786565 | COMPOSITION FOR THE TREATMENT OF AMYLOID-BETA ASSOCIATED DISEASES | Final Rejection | BASF SE |
| 18154498 | Alpha-Ketobutyrate, 2-Hydroxybutyrate, and Alpha-Ketoglutarate for Stimulating Hair Growth | Non-Final OA | The Regents of the University of California |
| 18001889 | A NUTRITIONAL COMPOSITION COMPRISING 3-HYDROXYBUTYRIC ACID TO IMPROVE THE GASTROINTESTINAL BARRIER | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18882674 | USE OF 2-HYDROXYBENZYLAMINE FOR THE TREATMENT OF SYSTEMIC LUPUS | Non-Final OA | Vanderbilt University |
| 16551594 | COMPOSITIONS AND METHODS FOR DELIVERING TETRAHYDROCANNABINOL AND KETONE BODIES | Final Rejection | AXCESS GLOBAL SCIENCES, LLC |
| 17790702 | Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism | Non-Final OA | The Trustees of Princeton University |
| 18560670 | SMALL MOLECULE-BASED BI-SPECIFIC IMMUNE CELL TETHERS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION | Non-Final OA | PURDUE RESEARCH FOUNDATION |
| 17773257 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTION | Final Rejection | UNIVERSITY OF SOUTH FLORIDA |
| 18694284 | COMPOUNDS AND METHODS FOR TREATING CANCERS THAT ARE MGMT DEFICIENT REGARDLESS OF MMR STATUS | Non-Final OA | Yale University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy46.7% of resolved applications examined by Irina Neagu were allowed (719 resolved cases), compared with 35.1% across Art Unit 1627 over the last five years.
This examiner's interview lift is +57.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Irina Neagu took 1,010 days on average from filing to allowance.
Irina Neagu examines applications in Art Unit 1627 in Tech Center 1700 (Chemistry & Materials).
